Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oruka Therapeutics, Inc. Director's Dealing 2015

Sep 21, 2015

32280_dirs_2015-09-21_20ab91a9-6b93-4cd7-8873-5c0a4f7d3e64.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARCA biopharma, Inc. (ABIO)
CIK: 0000907654
Period of Report: 2015-09-18

Reporting Person: Keuer Thomas A (Chief Operating Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2015-09-18 Common Stock S 680 $6.33 Disposed 17407 Direct

Footnotes

F1: Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person for satisfaction of their tax withholding obligation with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Equity Incentive Plan (the "Plan").

F2: Includes (i) remaining 2,143 previously reported shares issued as RSUs under the Plan that vests on 9/17/16, (ii) remaining 2,857 previously reported shares issued as RSUs under the Plan that vests in two equal installments beginning on 10/15/15, (iii) 3,664 previously reported shares issued as RSUs under the Plan that vest in three equal annual installments beginning on 2/27/16, and (iv) 3,621 previously reported shares issued as RSUs under the Plan that vest in three equal annual installments beginning April 2, 2016, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 5,122 previously reported shares of common stock owned.